vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $10.7M, roughly 1.3× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -342.3%, a 365.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 47.1%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
ABUS vs GOSS — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $13.8M |
| Net Profit | $2.5M | $-47.2M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | -333.6% |
| Net Margin | 23.5% | -342.3% |
| Revenue YoY | 522.2% | 47.1% |
| Net Profit YoY | 112.7% | -43.0% |
| EPS (diluted) | $0.01 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.8M | ||
| Q3 25 | — | $13.3M | ||
| Q2 25 | $10.7M | — | ||
| Q2 24 | — | $95.8M | ||
| Q1 24 | — | $0 | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | $0 | ||
| Q2 23 | $4.7M | $0 |
| Q4 25 | — | $-47.2M | ||
| Q3 25 | — | $-48.2M | ||
| Q2 25 | $2.5M | — | ||
| Q2 24 | — | $49.2M | ||
| Q1 24 | — | $-41.9M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | $-40.0M | ||
| Q2 23 | $-17.1M | $-42.5M |
| Q4 25 | — | -333.6% | ||
| Q3 25 | — | -369.4% | ||
| Q2 25 | 13.9% | — | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | — | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — |
| Q4 25 | — | -342.3% | ||
| Q3 25 | — | -362.7% | ||
| Q2 25 | 23.5% | — | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — |
| Q4 25 | — | $-0.21 | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | $0.01 | — | ||
| Q2 24 | — | $0.22 | ||
| Q1 24 | — | $-0.19 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | $-0.21 | ||
| Q2 23 | $-0.10 | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $136.9M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $-122.8M |
| Total Assets | $103.3M | $172.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $136.9M | ||
| Q3 25 | — | $180.2M | ||
| Q2 25 | $37.4M | — | ||
| Q2 24 | — | $354.5M | ||
| Q1 24 | — | $244.4M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | $328.9M | ||
| Q2 23 | $27.2M | $162.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — |
| Q4 25 | — | $-122.8M | ||
| Q3 25 | — | $-82.3M | ||
| Q2 25 | $83.0M | — | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | — | $26.7M | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | $104.6M | ||
| Q2 23 | $134.7M | $-62.8M |
| Q4 25 | — | $172.2M | ||
| Q3 25 | — | $208.8M | ||
| Q2 25 | $103.3M | — | ||
| Q2 24 | — | $373.4M | ||
| Q1 24 | — | $259.4M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | $347.9M | ||
| Q2 23 | $176.8M | $181.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $-48.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-48.3M | ||
| Q3 25 | — | $-36.2M | ||
| Q2 25 | $-15.7M | — | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | — | $-52.3M | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | $-34.5M | ||
| Q2 23 | $-19.6M | $-38.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
